PURPOSE: Approximately 5% to 8% of renal cell carcinoma (RCC) is hereditary. No guidelines exist for patient selection for RCC germline mutation testing. We evaluate how age of onset could indicate the need for germline mutation testing for detection of inherited forms of kidney cancer. PATIENTS AND METHODS: We analyzed the age distribution of RCC cases in the SEER-17 program and in our institutional hereditary kidney cancer population. The age distributions were compared by sex, race, histology, and hereditary cancer syndrome. Models were established to evaluate the specific age thresholds for genetic testing. RESULTS: The median age of patients with RCC in SEER-17 was 64 years, with the distribution closely approaching normalcy. Statistical differences were observed by race, sex, and subtype (P < .05). The bottom decile cutoff was ≤ 46 years of age and slightly differed by sex, race, and histology. The mean and median ages at presentation of 608 patients with hereditary kidney cancer were 39.3 years and 37 years, respectively. Although age varied by specific syndrome, 70% of these cases were found to lie at or below the bottom age decile. Modeling age-based genetic testing thresholds demonstrated that the 10th percentile maximized sensitivity and specificity. CONCLUSION: Early age of onset might be a sign of hereditary RCC. Even in the absence of clinical manifestations and personal/family history, an age of onset of 46 years or younger should trigger consideration for genetic counseling/germline mutation testing and may serve as a useful cutoff when establishing genetic testing guidelines.
PURPOSE: Approximately 5% to 8% of renal cell carcinoma (RCC) is hereditary. No guidelines exist for patient selection for RCC germline mutation testing. We evaluate how age of onset could indicate the need for germline mutation testing for detection of inherited forms of kidney cancer. PATIENTS AND METHODS: We analyzed the age distribution of RCC cases in the SEER-17 program and in our institutional hereditary kidney cancer population. The age distributions were compared by sex, race, histology, and hereditary cancer syndrome. Models were established to evaluate the specific age thresholds for genetic testing. RESULTS: The median age of patients with RCC in SEER-17 was 64 years, with the distribution closely approaching normalcy. Statistical differences were observed by race, sex, and subtype (P < .05). The bottom decile cutoff was ≤ 46 years of age and slightly differed by sex, race, and histology. The mean and median ages at presentation of 608 patients with hereditary kidney cancer were 39.3 years and 37 years, respectively. Although age varied by specific syndrome, 70% of these cases were found to lie at or below the bottom age decile. Modeling age-based genetic testing thresholds demonstrated that the 10th percentile maximized sensitivity and specificity. CONCLUSION: Early age of onset might be a sign of hereditary RCC. Even in the absence of clinical manifestations and personal/family history, an age of onset of 46 years or younger should trigger consideration for genetic counseling/germline mutation testing and may serve as a useful cutoff when establishing genetic testing guidelines.
Authors: S K Sidhar; J Clark; S Gill; R Hamoudi; A J Crew; R Gwilliam; M Ross; W M Linehan; S Birdsall; J Shipley; C S Cooper Journal: Hum Mol Genet Date: 1996-09 Impact factor: 6.150
Authors: I A Lubensky; L Schmidt; Z Zhuang; G Weirich; S Pack; N Zambrano; M M Walther; P Choyke; W M Linehan; B Zbar Journal: Am J Pathol Date: 1999-08 Impact factor: 4.307
Authors: M-H Wei; O Toure; G M Glenn; M Pithukpakorn; L Neckers; C Stolle; P Choyke; R Grubb; L Middelton; M L Turner; M M Walther; M J Merino; B Zbar; W M Linehan; J R Toro Journal: J Med Genet Date: 2005-06-03 Impact factor: 6.318
Authors: Christian P Pavlovich; Robert L Grubb; Kathleen Hurley; Gladys M Glenn; Jorge Toro; Laura S Schmidt; Carlos Torres-Cabala; Maria J Merino; Berton Zbar; Peter Choyke; McClellan M Walther; W Marston Linehan Journal: J Urol Date: 2005-05 Impact factor: 7.450
Authors: Laura S Schmidt; Michael L Nickerson; Debora Angeloni; Gladys M Glenn; McClellan M Walther; Paul S Albert; Michelle B Warren; Peter L Choyke; Carlos A Torres-Cabala; Maria J Merino; Joan Brunet; Victòria Bérez; Joan Borràs; Giovanni Sesia; Lindsay Middelton; John L Phillips; Catherine Stolle; Berton Zbar; Stephen E Pautler; W Marston Linehan Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: M M Walther; P L Choyke; G Weiss; C Manolatos; J Long; R Reiter; R B Alexander; W M Linehan Journal: J Urol Date: 1995-03 Impact factor: 7.450
Authors: Youfeng Yang; Cathy D Vocke; Christopher J Ricketts; Darmood Wei; Hesed M Padilla-Nash; Martin Lang; Carole Sourbier; J Keith Killian; Shawna L Boyle; Robert Worrell; Paul S Meltzer; Thomas Ried; Maria J Merino; Adam R Metwalli; W Marston Linehan Journal: Genes Chromosomes Cancer Date: 2017-07-24 Impact factor: 5.006
Authors: Maria I Carlo; A Ari Hakimi; Grant D Stewart; Gennady Bratslavsky; James Brugarolas; Ying-Bei Chen; W Marston Linehan; Eamonn R Maher; Maria J Merino; Kenneth Offit; Victor E Reuter; Brian Shuch; Jonathan A Coleman Journal: Eur Urol Date: 2019-07-18 Impact factor: 20.096
Authors: James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra Journal: Nat Rev Dis Primers Date: 2017-03-09 Impact factor: 52.329
Authors: Sarah S Bernards; Barbara M Norquist; Maria I Harrell; Kathy J Agnew; Ming K Lee; Tom Walsh; Elizabeth M Swisher Journal: Gynecol Oncol Date: 2015-12-21 Impact factor: 5.482
Authors: Douglas H Russell; Mitchell S Wachtel; Heiko W de Riese; Allan L Haynes; Werner T W de Riese Journal: Int Urol Nephrol Date: 2015-07-28 Impact factor: 2.370